Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical presentation and mortality in hospitalized patients aged 80+ years with COVID-19-A retrospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Det danske screeningsprogram for hæmoglobinopatier

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Blodsygdomme

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisningpeer review

  4. Treatment of monogenic disorders with viral transduced haematopoietic stem cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Annelies J van Vuren
  • Michele F Eisenga
  • Stephanie van Straaten
  • Andreas Glenthøj
  • Carlo A J M Gaillard
  • Stephan J L Bakker
  • Martin H de Borst
  • Richard van Wijk
  • Eduard J van Beers
Vis graf over relationer

Recently, erythropoietin (EPO) was identified as regulator of fibroblast growth factor 23 (FGF23). Proteolytic cleavage of biologically active intact FGF23 (iFGF23) results in the formation of C-terminal fragments (cFGF23). An increase in cFGF23 relative to iFGF23 suppresses FGF receptor signaling by competitive inhibition. EPO lowers the i:cFGF23 ratio, thereby overcoming iFGF23-mediated suppression of erythropoiesis. We investigated EPO-FGF23 signaling and levels of erythroferrone (ERFE) in 90 patients with hereditary hemolytic anemia (www.trialregister.nl [NL5189]). We show, for the first time, the importance of EPO-FGF23 signaling in hereditary hemolytic anemia: there was a clear correlation between total FGF23 and EPO levels (r = +0.64; 95% confidence interval [CI], 0.09-0.89), which persisted after adjustment for iron load, inflammation, and kidney function. There was no correlation between iFGF23 and EPO. Data are consistent with a low i:cFGF23 ratio. Therefore, as expected, we report a correlation between EPO and ERFE in a diverse set of hereditary hemolytic anemias (r = +0.47; 95% CI, 0.14-0.69). There was no association between ERFE and total FGF23 or iFGF23, which suggests that ERFE does not contribute to the connection between FGF23 and EPO. These findings open a new area of research and might provide potentially new druggable targets with the opportunity to ameliorate ineffective erythropoiesis and the development of disease complications in hereditary hemolytic anemias.

OriginalsprogEngelsk
TidsskriftBlood advances
Vol/bind4
Udgave nummer8
Sider (fra-til)1678-1682
Antal sider5
ISSN2473-9529
DOI
StatusUdgivet - 28 apr. 2020

Bibliografisk note

© 2020 by The American Society of Hematology.

ID: 62088621